Эффективность контроля частоты сердечных сокращений у больных сахарным диабетом и ишемической болезнью сердца: возможно ли изменить ситуацию?

1. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. Endocrine practice 2007; 13 (Suppl. 1): 3–68.
2. Smooke S, Horwich TB, Fonarow GS. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005; 149: 168–74.
3. Malmberg K, Herlitz J, Hjalmarson A, Ruden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infraction. Retrospective data from two large scale studies. Eur Heart J 1989; 10: 423–8.
4. Malmberg K, Ryden L, Hamsten A et al. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res 1997; 34: 248–53.
5. Фомин И.В., Поляков Д.С. Бета-адреноблокаторы вчера, сегодня, завтра: смогут ли они остаться в группе основных лекарственных средств? Системные гипертензии. 2011; 2: 36–42.
6. Основные положения рекомендаций Европейского общества кардиологов по ведению больных стабильной стенокардией (2006 г.). Эффективная фармакотерапия в кардиологии и ангиологии. 2007; 2: 1–9.
7. Timmer JR, van der Horst IC, de Luca G et al. Myocardial Infarction Study Group. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol 2005; 95: 1375–7.
8. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14 (8): 803–69.
9. Фомин И.В., Валикулова Ф.Ю. Антиангинальный эффект длительного применения Ивабрадина у больных ИБС и СД в условиях амбулаторной практики. Кардиология. 2009; 3: 5–15.
10. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur H J 2007; 28: 88–136.
11. Schroeder EB, Chambless LE, Liao D et al. Atherosclerosis Risk in Communities (ARIC) Study. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2005; 28: 668–74.
12. O’Brien IA, O’Hara JP, Lewin IG et al. The prevalence of autonomic neuropathy in insulin-dependent diabetes: a controlled study based on heart rate variability. Q J Med 1986; 61: 957–67.
13. Singh JP, Larson MG, O’Donnell CJ et al. Association of hyperglycaemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000; 86: 309–12.
14. Suarez GA, Clark VM, Norell JE et al. Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study. J Neurol Neurosurg Psychiatry 2005; 76: 240–5.
15. Forsen A, Kangro M, Sterner G et al. A 14-year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy. Diabet Med 2004; 21: 852–8.
16. Jouven X, Lemaitre RN, Rea TD et al. Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J 2005; 26: 2142–7.
17. Braman N. Singh. Morbidity in Cardiovascular Disorders; Impact of Reduced Heart Rate. J Cardiovasc Pharmacol Ther 2001; 6 (4): 313–31.
18. Di Francesco D, Camm A. Heart rate Lowering by Specific and Selective If Current Inhibition with Ivabradin. Drugs 2004; 64 (16): 1757–65.
19. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl. 2): E1–E40.
20. Shaper A, Wannamethee G, Macfarlane P, Walker M. Heart rate, ischaemic heart disease and sudden death in middle-aged British men. Br Heart J 1993; 70: 49–55.
21. Reil JC, Bohm M. BEAUTIFUL results – the slower, the better? Lancet 2008; DOI: 10.1016/ S0140-6736 (08) 61172–1.
22. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009; 30: 2337–45.
23. Freemantle N, Cleland J, Young P et al. b-Blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ 1999; 318: 1730–7.
24. Brophy J, Joseph L, Rouleau J. b-Blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001; 134: 550–60.
25. Kjekshus J. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F–49F.
26. Bangalore S et al. b-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. 
JAMA 2012; 308 (13): 1340–9.
27. Cleland JGF, Coletta AP, Freemantle N et al. Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure. Eur J Heart Fail 2010; 12: 197–201.
28. Lowrie R, Mair FS, Greenlaw N et al. The Heart failure and Optimal Outcomes from Pharmacy Study (HOOPS): rationale, design, and baseline characteristics. Eur J Heart Fail 2011; 13 (8): 917–24.
29. Tardif JC, O’Meara E, Komajda M et al. Resting heart rate and incident heart failure in apparently healthy men and women in the EPIC-Norfolk study. Eur Heart J 2011; 32 (20): 2507–15.
30. Sarraf M, Francis GS. It Is All About Heart Rate. Or Is It? J Am Coll Cardiol 2012; 59 (22): 1946–7.
31. Steg PG, Greenlaw N, Tardif JC et al on behalf of the CLARIFY Registry Investigators. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J 2012; 33: 2831–40.
32. Tardif J, Ford I, Tendera M et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529–36.
33. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. The Lancet 2008; 372 (96410): 807–16.
34. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. The Lancet 2008; 372 (9641): 817–21.

Ф.Ю.Валикулова, И.В.Фомин, Е.В.Гурвич 

ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава РФ